ClinicalTrials.gg
Sign In

Drug

GSK2141795 clinical trials

Also written GSK2141795 and Uprosertib.

studies test it
11
open now
0
in phase 3
0
first study started
2009

How studies write it

Studies that test it under each name

Name

Oral Akt Inhibitor GSK2141795
6
Akt Inhibitor GSK2141795
2

Development codes

GSK2141795
11

Other names

Uprosertib
4

Studies by the year they started

11 studies that test it; most in 2013 (8)

Studies that test GSK2141795, by start year
YearStudies
20091
20102
20138

By phase

A phase 1/2 study counts in both.

Phase 1
5
Phase 2
7

What it is tested for

Each study’s main condition, where its own words name it.

Melanoma
2
Uveal Melanoma
1
Multiple Myeloma
1
Adenocarcinoma, Clear Cell
1
Carcinoma
1
Uterine Cervical Neoplasms
1
Leukemia, Myeloid, Acute
1

Who runs them

Industry 3 · Other 8

National Cancer Institute (NCI) (6) · GlaxoSmithKline (3) · Adil Daud (1) · Dana-Farber Cancer Institute (1)

Often tested with

Tested in the same studies.

Trametinib (6) · Dabrafenib mesylate (1) · Dabrafenib (1)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses GSK2141795 is read from its arms, and is right about nine times in ten.

Testing it · 11